ResMed Inc. Lets Investors Breath Easy

Nov. 13, 2022 11:37 PM ETResMed Inc. (RMD)PHG4 Comments
Harold Goldmeier profile picture
Harold Goldmeier


  • ResMed is a potential opportunity for retail value investors to profit from this low-risk market leader, but there are several issues that worry us - the share price is high.
  • The company revenue consistently grows in a niche of the healthcare device industry that will annually increase about 6% to almost $6B in revenue.
  • ResMed's CPAP machine and management software are the most popular on the market. We expect the average price target to rise significantly over the next 12 months.
Sleep Apnea Oxygen Mask Equipment

AndreyPopov/iStock via Getty Images

We reiterate in this article our bullish position on sleep and respiratory medical device maker ResMed Inc. (NYSE:RMD). We wrote several bullish articles over five years beginning when its shares sold in the $60 and $70 range. The stock shot to

This article was written by

Harold Goldmeier profile picture
I write for retail value investors who cannot afford to lose money but sometimes like to take a risk. I speak for free to community and school groups. I was teaching business, social/political activism, and Middle East politics to international university students in Tel Aviv b4 the pandemic hit. I consult with startups and mid-level companies. I co-manage Goldmeier Investments LLC with my son Daniel. I founded the Sappanos Decorating Centers, Chicago, with more than 70 employees and real estate holdings in excess of $15m. I am a former Research and Teaching Fellow at Harvard and Assoc. Prof Tufts Medical School.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.